<DOC>
	<DOCNO>NCT00972504</DOCNO>
	<brief_summary>This randomise , double-blind , placebo-controlled 4-period cross-over study assess efficacy safety repeat dose intranasal GSK1004723 ( 1000Âµg ) , oral GSK835726 ( 10mg ) cetirizine ( 10mg ) environmental challenge chamber subject seasonal allergic rhinitis .</brief_summary>
	<brief_title>723/726 Proof Concept Study Allergen Challenge Chamber Hannover</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>Subject healthy apart seasonal allergic rhinitis , determine physician . Can mild asthma . Males female use contraceptive Aged 18 65 Weight 50kg+ , BMI 1932 kg/m2 Exhibit response Challenge Chamber skin prick test . Nonsmoker Capable give informed consent AST ALT &lt; 2xULN ; alkaline phosphatase bilirubin &lt; or=1.5xULN No nasal structural abnornmality/polyposis , surgery , infection . respiratory disease , mild asthma seasonal allergic rhinitis participate another clinical study within 30 day . Subject donate unit blood within 1 month Use prescription nonprescription drug , include vitamin st john 's wort within 7 day trial . History sensitivty drug History alcohol/drug abuse within 12 month . Positive Hepatitis B antibody test Positive HIV antibody test Risk noncompliance study protocol Pregnant llactating female Perenial allergic rhinitis Administration oral , injectable dermal corticosteriods within 8 week , intranasal inhale within 3 week . Past present disease may affect outcome , judge investigator Specific Immunotherapy within 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Proof concept</keyword>
</DOC>